Cemiplimab + Fianlimab + Pemetrexed (Alimta) + Cisplatin + Carboplatin (AUC 5)
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pleural Mesotheliomas
Conditions
Pleural Mesotheliomas
Trial Timeline
Feb 1, 2026 → Sep 1, 2029
NCT ID
NCT07234058About Cemiplimab + Fianlimab + Pemetrexed (Alimta) + Cisplatin + Carboplatin (AUC 5)
Cemiplimab + Fianlimab + Pemetrexed (Alimta) + Cisplatin + Carboplatin (AUC 5) is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Pleural Mesotheliomas. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07234058. Target conditions include Pleural Mesotheliomas.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07234058 | Phase 2 | Recruiting |
Competing Products
20 competing products in Pleural Mesotheliomas